Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in liver transplantation.

Russell H Wiesner1, Jorge Rakela, Michael B Ishitani

  • 1Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA. rwiesner@mayo.edu

Mayo Clinic Proceedings
|February 14, 2003
PubMed
Summary

Liver transplant advancements face donor organ shortages, leading to patient deaths. New allocation policies and treatments for recurrent hepatitis C aim to improve outcomes and reduce waiting list mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Genetic Risk Factors Associated With Herbal and Dietary Supplement-Induced Acute Liver Failure Using Whole Exome Sequencing Analysis.

Gastro hep advances·2025
Same author

CON: A multi-vendor organ procurement and transplantation network (OPTN) will not improve liver procurement and use.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2025
Same author

Primary Ovarian Non-Gestational Placental Site Trophoblastic Tumor in a Pediatric Patient: A Case Report and Review of the Literature.

Pediatric blood & cancer·2025
Same author

Genetic Variants of GBP4: Reduced Risks for Drug-Induced Acute Liver Failure in Non-Finnish European Population.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Rapidly recurrent trichobezoar management.

BMJ case reports·2024
Same author

Contrast-enhanced computed tomography for ex vivo assessment of human kidneys: A proof-of-concept study.

Artificial organs·2024

Area of Science:

  • Hepatology
  • Transplantation Medicine
  • Immunology

Background:

  • Donor organ shortages significantly impact liver transplantation, causing high mortality rates among patients awaiting organs.
  • Strategies to expand the donor pool include utilizing marginal donors, living donation, split liver grafts, domino transplantation, and hepatic support systems.
  • Recurrent liver diseases, especially hepatitis C, pose a significant challenge, necessitating effective therapies to prevent graft recurrence and retransplantation.

Purpose of the Study:

  • To review current challenges and advancements in liver transplantation.
  • To discuss strategies for expanding the donor pool and improving organ allocation.
  • To explore therapeutic approaches for recurrent hepatitis C and optimize immunosuppression.

Main Methods:

Related Experiment Videos

  • Review of current literature and clinical practices in liver transplantation.
  • Analysis of liver allocation policy changes, including the Model for End-Stage Liver Disease (MELD) system.
  • Evaluation of therapeutic strategies for recurrent hepatitis C and advancements in immunosuppressive regimens.

Main Results:

  • Implementation of the MELD allocation system is expected to reduce waiting list deaths.
  • Pegylated interferon combined with ribavirin shows promise in managing recurrent hepatitis C.
  • Advances in immunosuppression have decreased rejection rates but introduced metabolic complications affecting long-term survival and quality of life.

Conclusions:

  • Addressing donor organ shortages and improving allocation policies are crucial for liver transplantation.
  • Effective management of recurrent hepatitis C is vital to prevent graft loss and retransplantation.
  • Personalized immunosuppressive strategies are needed to balance efficacy with metabolic complications for improved long-term patient outcomes.